))
Ep 67 - AAM's Craig Burton on Opportunities, Challenges of U.S. Biosimilars Market
Manage episode 438374649 series 3571902
Conteúdo fornecido por BioCentury. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por BioCentury ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
There is good news in this year’s Association for Accessible Medicines report on savings from biosimilars, including a 30% increase over the last year in savings attributed to biosimilars. The report also explores the economic, policy and regulatory headwinds that are preventing the industry from generating savings at a level that would have a dramatic effect on the U.S. healthcare system.
In an interview with Washington Editor Steve Usdin on The BioCentury Show, Craig Burton, executive director of AAM’s Biosimilars Council, calls out business practices and government policies that are holding the industry back and discusses the ways a robust biosimilars market could promote biomedical innovation.
View full story: https://www.biocentury.com/article/653459
#biotech #biopharma #pharma #lifescience #biosimilars #politics #policy #law
00:00 - Introduction
03:45 - IRA
13:38 - Humira
20:44 - Biosimilars Pipeline
Capítulos
1. Ep 67 - AAM's Craig Burton on Opportunities, Challenges of U.S. Biosimilars Market (00:00:00)
2. IRA (00:03:45)
3. Humira (00:13:38)
4. Biosimilars Pipeline (00:20:44)
21 episódios
Compartilhar
